Eton Pharmaceuticals (ETON) Cost of Revenue (2019 - 2025)
Historic Cost of Revenue for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $14.6 million.
- Eton Pharmaceuticals' Cost of Revenue rose 26310.29% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.5 million, marking a year-over-year increase of 9454.37%. This contributed to the annual value of $15.6 million for FY2024, which is 4743.41% up from last year.
- According to the latest figures from Q3 2025, Eton Pharmaceuticals' Cost of Revenue is $14.6 million, which was up 26310.29% from $7.0 million recorded in Q2 2025.
- In the past 5 years, Eton Pharmaceuticals' Cost of Revenue registered a high of $14.6 million during Q3 2025, and its lowest value of $174000.0 during Q2 2021.
- Over the past 5 years, Eton Pharmaceuticals' median Cost of Revenue value was $2.3 million (recorded in 2023), while the average stood at $3.1 million.
- In the last 5 years, Eton Pharmaceuticals' Cost of Revenue surged by 147758.62% in 2022 and then crashed by 7718.82% in 2025.
- Quarter analysis of 5 years shows Eton Pharmaceuticals' Cost of Revenue stood at $372000.0 in 2021, then soared by 474.73% to $2.1 million in 2022, then skyrocketed by 72.26% to $3.7 million in 2023, then skyrocketed by 40.4% to $5.2 million in 2024, then skyrocketed by 182.42% to $14.6 million in 2025.
- Its Cost of Revenue was $14.6 million in Q3 2025, compared to $7.0 million in Q2 2025 and $675000.0 in Q1 2025.